ClinicalTrials.gg
CompletedNCT04091945Updated Jan 22, 2026Results posted

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

A Phase 2 interventional study of LT3001 Drug Product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Ischemic Stroke with a site in Taiwan — 18 open to participants now, 21 under way, 3 of them phase 3. Ischemic Stroke · Taiwan.

Enrollment
42nd of 52
24 · median 73
Started
2020
with 5 others
Phase 2
9 of 64
2 open now
Registered
27th of 64
by date
Lead sponsor
3 of 64
Lumosa Therapeutics Co., Ltd.

Among the 64 studies in Ischemic Stroke with a site in Taiwan, this one is the 42nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2020, is one of 9 in phase 2, and was the 27th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

18 of the 64 studies in Ischemic Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Ischemic Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 90 years
  • NIHSS of 4 to 30
  • Diagnosis of AIS within 24 hours after stroke symptoms onset

Exclusion criteria

Exclusion Criteria:

  • Treatement with approved drug during the current AIS
  • Pre-stroke disability
  • Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor, arteriovenous malformations, other central nervous system lesions that could increase bleeding risk, or aneurysm requiring treatment
  • Suspected subarachnoid hemorrhage
  • Seizure
  • Uncontrolled hypertension
  • >1.7 and/or abnormal aPTT or count \<100,000/mm3
  • Blood glucose concentration \<50 mg/dL or >400 mg/dL
  • Lactating or pregnant subjects or those planning to become pregnant during the study
  • Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa inhibitors within 48 hours
  • AIS, myocardial infarction, serious head trauma or major surgery within 90 days
  • Bleeding event within 21 days
  • Puncture of noncompressible vessels within 7 days
  • Severe hepatic, renal, and/or infectious disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    LT3001 Drug Product

    Drug: LT3001 Drug Product

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS.

    Compare the the percentage of subject having sICH between LT3001 drug product and Placebo.

    Time frame: Within 36 hours

07

Results

Posted Dec 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneLT3001 Drug ProductPlacebo
Started168
Completed147
Not completed21

Outcome measures

PrimaryThe Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS.

Compare the the percentage of subject having sICH between LT3001 drug product and Placebo.

Time frame:
Within 36 hours
Reported as:
Count of participants · Participants
The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS.
ParticipantsLT3001 Drug ProductPlacebo
The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS.00

Adverse events

Collected over From the time the subject received the IP until the last follow-up visit, approximately 92 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LT3001 Drug Product1/16 (6.3%)4/16 (25%)16/16 (100%)
Placebo1/8 (12.5%)2/8 (25%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventLT3001 Drug ProductPlacebo
PneumoniaInfections and infestations1/161/8
COVID-19Infections and infestations0/161/8
Staphylococcal infectionInfections and infestations0/161/8
Stroke in evolutionNervous system disorders2/160/8
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/161/8
Respiratory arrestRespiratory, thoracic and mediastinal disorders0/161/8
Cerebral infarctionNervous system disorders1/160/8
Bronchial neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/160/8
Most frequent other events
Showing 10 of 29
Most frequent other events
EventLT3001 Drug ProductPlacebo
ConstipationGastrointestinal disorders10/164/8
HeadacheNervous system disorders2/162/8
HypertensionVascular disorders2/162/8
PneumoniaInfections and infestations2/162/8
C-reactive protein increasedInvestigations1/162/8
DiarrhoeaGastrointestinal disorders3/162/8
HyponatraemiaMetabolism and nutrition disorders1/162/8
AtelectasisRespiratory, thoracic and mediastinal disorders0/162/8
NephrolithiasisRenal and urinary disorders0/162/8
CoughRespiratory, thoracic and mediastinal disorders3/160/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)LT3001 Drug ProductPlaceboTotal
Mean62.1 ± 12.6367.6 ± 9.2463.9 ± 11.71
Sex: Female, Male
Sex: Female, Male(Participants)LT3001 Drug ProductPlaceboTotal
Female415
Male12719
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LT3001 Drug ProductPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino15318
Unknown or Not Reported156
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LT3001 Drug ProductPlaceboTotal
American Indian or Alaska Native000
Asian15318
Native Hawaiian or Other Pacific Islander000
Black or African American000
White156
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • JFK Neuroscience Institute, JFK Medical Center
    Edison, New Jersey 08837, United States
  • The Ohio State University - Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Chattanooga Center for Neurologic Research
    Chattanooga, Tennessee 37403, United States
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, Taiwan
  • Linkou Chang Gung Memorial Hospital
    New Taipei City, Taiwan
  • Taipei Medical University - Shuang Ho Hospital
    New Taipei City, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
09

References and documents

Publications

  • Chao AC, Lee TH, Pettigrew LC, Hannawi Y, Huang HY, Chi NF, Chan L, Chen PL, Devlin T. Intravenous Odatroltide for Acute Ischemic Stroke Within 24 Hours of Onset: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Drug Des Devel Ther. 2024 Jun 6;18:2033-2042. doi: 10.2147/DDDT.S460831. eCollection 2024. PubMed 38859883 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Feb 2021, 12 months.

Results were first posted in Dec 2025, 4 years 10 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 12 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 17, 2019
StartActual
Jan 27, 2020
Primary completionActual
Feb 22, 2021
CompletionActual
Feb 22, 2021
Results first posted
Dec 30, 2025
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04091945
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Jan 27, 2020
Primary completion
Feb 22, 2021
Completion
Feb 22, 2021
Results posted
Dec 30, 2025
Last update
Jan 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LT3001

Start the discussion